News & Events about Clene Inc.
SALT LAKE CITY, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, Clene) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company today announced that it will participate in Renmark Financial Communications Inc.s ...
Funding Demonstrates Importance of Working with Private Sector to Improve Lives of Marylanders, says Governor HoganSALT LAKE CITY, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries Clene) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage...
Globe Newswire
2 months ago
CNM-Au8 demonstrated low contrast vision improvement and global neurological improvement (low contrast vision, cognition, upper extremity function, and walking speed) in stable MS patients as adjunct to background immunomodulating disease modifying therapies (DMTs)No approved MS DMTs have shown ...
Globe Newswire
2 months ago
Secondary survival endpoint for the CNM-Au8 30 mg dose investigated in the Healey ALS Platform Trial demonstrated a >90% reduction in the risk of death or death equivalent (permanently assisted ventilation) and risk of death alone at 24 weeks. This survival benefit was consistent with prior results ...
Clene Inc. (NASDAQ:CLNN Get Rating) Director David J. Matlin purchased 2,871,287 shares of the stock in a transaction dated Wednesday, November 2nd. The shares were purchased at an average price of $1.01 per share, with a total value of $2,899,999.87. Following the transaction, the director now ...